( NASDAQ-NMS:ISIS )

News from Isis Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

18 Dec, 2015, 09:30 ET Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc.  Ionis...


17 Dec, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating...


11 Dec, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx...


10 Nov, 2015, 07:00 ET Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the...


09 Nov, 2015, 07:00 ET Isis Reports Financial Results and Highlights for Third Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted...


08 Nov, 2015, 10:30 ET Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of...


06 Nov, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...


05 Nov, 2015, 07:00 ET Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to...


04 Nov, 2015, 07:00 ET Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Sunday, November 8 at 1:00 p.m. Eastern Time to...


03 Nov, 2015, 06:00 ET Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive preliminary results from an ongoing investigator sponsored, open-label...


30 Oct, 2015, 07:00 ET Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal...


27 Oct, 2015, 07:00 ET Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, November 3 at 8:00 a.m. Eastern Time to...


26 Oct, 2015, 07:00 ET ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the initiation...


23 Oct, 2015, 07:00 ET Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, November 9 at 11:30 a.m. Eastern Time to...


15 Oct, 2015, 19:33 ET Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated an open-label extension study, SHINE.  The SHINE study...


11 Sep, 2015, 07:00 ET Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its collaboration with AstraZeneca to discover and develop antisense drugs for...


03 Sep, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...


21 Jul, 2015, 07:00 ET Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with...


04 May, 2015, 09:00 ET Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and...


10 Feb, 2015, 07:00 ET Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the...


05 Feb, 2015, 07:00 ET Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating...


04 Feb, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...


03 Feb, 2015, 07:00 ET Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2...


14 Jan, 2015, 07:00 ET Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the...


08 Jan, 2015, 07:00 ET Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial...